Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

Table 4

Probabilities of patients developing haematological toxicities stratified by chemotherapy regimen.

	Probability of developing
	neutropenia	febrile neutropenia	thrombocytopenia	anaemia
First-line treatments
Doxorubicin/ifosfamide	0.82	0.12	0.23	0.35
	[23, 24, 26, 30]	[24, 26]	[17, 23, 24, 26, 30]	[23, 26, 30]
Trabectedin	0.33	0.00	0.00	0.03
	[34]	[34]	[34]	[34]
Second-line treatments
CYVADIC^*∧	0.52	0.19	0.17	0.16
Docetaxel	0.90	0.12	0.03	0.08
	[36, 37]	[35, 37]	[35–37]	[35–37]
Doxorubicin	0.84	0.19	0.09	0.18*
	[39]	[39]	[39]
Doxorubicin/ifosfamide*	0.52	0.19	0.17	0.18
Gemcitabine	0.18	0.07	0.18	0.11
	[40, 41, 43, 47, 71]	[33, 40, 41, 43, 71]	[33, 40–43, 46, 71]	[40–43, 71]
Gemcitabine/dacarbazine	0.46 [49]	0.19*	0.12 [49]	0.23 [49]
Gemcitabine/docetaxel	0.31	0.09	0.33	0.18
	[52, 54]	[52, 54]	[40, 52, 54]	[52, 54]
Gemcitabine/paclitaxel*	0.52	0.19	0.17	0.16
Gemcitabine/vinorelbine	0.38 [56]	0.08 [56]	0.10 [56]	0.05 [56]
Ifosfamide	0.82	0.39	0.13	0.12
	[57–60]	[58, 59]	[57–60]	[57–59]
Ifosfamide/epirubicin*	0.52	0.19	0.17	0.18
Liposomal doxorubicin*	0.07	0.02	0.00	0.35
Trabectedin	0.50	0.06	0.16	0.18
	[19, 34, 61, 64, 65, 67]	[19, 34, 61, 65]	[19, 34, 61, 64, 65, 67]	[19, 34, 61, 65]
Trofosfamide	0.52*	0.19*	0.17*	0.25 [70]
Trofosfamide/etoposide*	0.52	0.19	0.17	0.16

 ^∧CYVADIC: cyclophosphamide, vincristine, adriamycin, and dacarbazine.
*Values were estimated.